Does the choice between ACE-inhibitors and AT1 antagonists affect serum erythropoietin levels in class III and IV CHF patients?
Class III and IV congestive heart failure (CHF) patients
ACE-inhibitors or AT1 antagonists
Serum Erythropoietin (Epo) levelssurrogate
The study hypothesizes that AT1 antagonists may be preferable to ACE-inhibitors for achieving desirable erythropoietin increases in severe heart failure.
We suggest that a desirable Epo increase in class III and IV CHF patients could be achieved by either recombinant human Epo administration or, possibly, by appropriate selection of the concomitant medical therapy. A large prospective study shall investigate the possible advantage of AT(1) antagonists over ACE-inhibitors with regard to Epo effect.
Building similarity graph...
Analyzing shared references across papers
Loading...
Bidisha Chatterjee
Urs E. Nydegger
Paul Mohaçsi
European Journal of Heart Failure
University of Bern
University Hospital of Bern
Swiss Continence Foundation
Building similarity graph...
Analyzing shared references across papers
Loading...
Chatterjee et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d959a85e5bcb4e3b835aed — DOI: https://doi.org/10.1016/s1388-9842(00)00110-0